

Carla De Giovanni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9282732/publications.pdf>

Version: 2024-02-01

111
papers

4,365
citations

94433

37
h-index

114465

63
g-index

112
all docs

112
docs citations

112
times ranked

4728
citing authors

#	ARTICLE	IF	CITATIONS
1	2011: the immune hallmarks of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 319-326.	4.2	316
2	Interleukin 12-mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 1998, 188, 589-596.	8.5	291
3	Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice. <i>Journal of Experimental Medicine</i> , 2001, 194, 1195-1206.	8.5	218
4	TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. <i>Clinical and Experimental Metastasis</i> , 1983, 1, 373-380.	3.3	203
5	Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neu Transgenic Mice. <i>Cancer Research</i> , 2004, 64, 2858-2864.	0.9	143
6	Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. <i>International Journal of Cancer</i> , 2002, 101, 11-16.	5.1	96
7	Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment. <i>Human Molecular Genetics</i> , 2014, 23, 1453-1466.	2.9	96
8	Dra1 Is a P53-Responsive Gene Whose Four and a Half Lim Domain Protein Product Induces Apoptosis. <i>Journal of Cell Biology</i> , 2000, 151, 495-506.	5.2	93
9	Molecular and cellular biology of rhabdomyosarcoma. <i>Future Oncology</i> , 2009, 5, 1449-1475.	2.4	91
10	A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene <i>MTND1</i> , an <i>Oncojanus</i> Function. <i>Cancer Research</i> , 2011, 71, 6220-6229.	0.9	90
11	Inhibition of tumor growth and enhancement of metastasis after transfection of the β -interferon gene. <i>International Journal of Cancer</i> , 1993, 55, 320-329.	5.1	89
12	Immunoprevention of Mammary Carcinoma in HER-2/neu Transgenic Mice Is IFN- β and B Cell Dependent. <i>Journal of Immunology</i> , 2004, 173, 2288-2296.	0.8	88
13	Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine. <i>Cancer Research</i> , 2004, 64, 4001-4009.	0.9	87
14	Delivery of CD44 shRNA/Nanoparticles within Cancer Cells. <i>Journal of Biological Chemistry</i> , 2009, 284, 12432-12446.	3.4	84
15	Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells. <i>Cancer Research</i> , 2004, 64, 1730-1736.	0.9	83
16	Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9039-9044.	7.1	83
17	<i>In silico</i> Modeling and <i>In vivo</i> Efficacy of Cancer-Preventive Vaccinations. <i>Cancer Research</i> , 2010, 70, 7755-7763.	0.9	78
18	Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2 α^{flx} /Il2rg α^{flx} Mice and Treatment with PI3K Inhibitor. <i>PLoS ONE</i> , 2012, 7, e39626.	2.5	78

#	ARTICLE	IF	CITATIONS
19	The occurrence of multiple steroid hormone receptors in disease-free and neoplastic human ovary. <i>Cancer</i> , 1981, 47, 1297-1302.	4.1	75
20	p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. <i>International Journal of Cancer</i> , 2000, 87, 186-194.	5.1	75
21	Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. <i>Cancer & Metabolism</i> , 2013, 1, 11.	5.0	75
22	The Metastatic Ability of Ewing's Sarcoma Cells Is Modulated by Stem Cell Factor and by Its Receptor c-kit. <i>American Journal of Pathology</i> , 2000, 157, 2123-2131.	3.8	73
23	Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. <i>Journal of Clinical Investigation</i> , 2004, 113, 709-717.	8.2	64
24	Rethinking herpes simplex virus: the way to oncolytic agents. <i>Reviews in Medical Virology</i> , 2011, 21, 213-226.	8.3	63
25	Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. <i>International Journal of Cancer</i> , 1998, 77, 937-941.	5.1	58
26	Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibodyâ€“cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. <i>Vaccine</i> , 2003, 21, 1317-1326.	3.8	57
27	Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: Effects on tumorigenicity, metastatic potential and immune response. <i>International Journal of Cancer</i> , 2000, 87, 574-581.	5.1	56
28	A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins. <i>Cancer Research</i> , 2010, 70, 2604-2612.	0.9	54
29	Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. <i>Cancer Research</i> , 2003, 63, 2728-32.	0.9	53
30	Antimetastatic Activity of a Preventive Cancer Vaccine. <i>Cancer Research</i> , 2007, 67, 11037-11044.	0.9	47
31	Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells. <i>Gene</i> , 2001, 274, 139-149.	2.2	46
32	Cancer immunoprevention. <i>Future Oncology</i> , 2005, 1, 57-66.	2.4	43
33	Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. <i>American Journal of Pathology</i> , 2005, 166, 1205-1216.	3.8	43
34	Establishment and characterization of a new cell line from primary human breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 1993, 28, 251-260.	2.5	42
35	Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. <i>British Journal of Cancer</i> , 1995, 72, 1224-1229.	6.4	42
36	Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma. <i>Clinical and Experimental Metastasis</i> , 1990, 8, 215-224.	3.3	39

#	ARTICLE	IF	CITATIONS
37	Vaccines and Other Immunological Approaches for Cancer Immunoprevention. <i>Current Drug Targets</i> , 2011, 12, 1957-1973.	2.1	39
38	Interferon (IFN)- γ Gene Transfer into TS/A Adenocarcinoma Cells and Comparison with IFN- α . <i>American Journal of Pathology</i> , 1999, 154, 1211-1222.	3.8	38
39	Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. <i>PLoS Pathogens</i> , 2013, 9, e1003155.	4.7	36
40	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. <i>Oncogene</i> , 1999, 18, 739-746.	5.9	35
41	Reversal of malignant phenotype in human osteosarcoma cells transduced with the alkaline phosphatase gene. <i>Bone</i> , 2000, 26, 215-220.	2.9	35
42	The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. <i>Cancer Research</i> , 2003, 63, 2158-63.	0.9	34
43	RMZ: A new cell line from a human alveolar rhabdomyosarcoma. In vitro expression of embryonic myosin. <i>British Journal of Cancer</i> , 1986, 54, 1009-1014.	6.4	32
44	The Immune Response Elicited by Mammary Adenocarcinoma Cells Transduced with Interferon- β and Cytosine Deaminase Genes Cures Lung Metastases by Parental Cells. <i>Human Gene Therapy</i> , 1998, 9, 217-224.	2.7	30
45	Interferon-mediated enhancement of metastasis. Are MHC antigens involved?. <i>Clinical and Experimental Metastasis</i> , 1987, 5, 277-287.	3.3	29
46	HER/erbB Receptors as Therapeutic Targets of Immunotoxins in Human Rhabdomyosarcoma Cells. <i>Journal of Immunotherapy</i> , 2002, 25, 314-323.	2.4	29
47	Glucocorticoid receptor and in vitro sensitivity to steroid hormones in human lymphoproliferative diseases and myeloid leukemia. <i>Cancer</i> , 1982, 49, 623-632.	4.1	28
48	Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. <i>International Journal of Cancer</i> , 2003, 105, 384-389.	5.1	28
49	Immunological and non-immunological influence of H-2Kb gene transfection on the metastatic ability of B16 melanoma cells. <i>International Journal of Cancer</i> , 1991, 48, 270-276.	5.1	27
50	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. <i>Breast Cancer Research</i> , 2014, 16, R10.	5.0	27
51	High metastatic efficiency of human sarcoma cells in Rag2/ γ c double knockout mice provides a powerful test system for antimetastatic targeted therapy. <i>European Journal of Cancer</i> , 2010, 46, 659-668.	2.8	26
52	Multiple steroid hormone receptors in normal and abnormal human endometrium. <i>Journal of Cancer Research and Clinical Oncology</i> , 1980, 98, 173-183.	2.5	24
53	17 β -estradiol, 5 α -Dihydrotestosterone, Progesterone and Cortisol Receptors in Normal and Neoplastic Human Endometrium. <i>Tumori</i> , 1979, 65, 241-253.	1.1	22
54	High-metastatic clones selected in vitro from a recent spontaneous BALB/c mammary adenocarcinoma cell line. <i>Clinical and Experimental Metastasis</i> , 1984, 2, 251-259.	3.3	20

#	ARTICLE	IF	CITATIONS
55	Concomitant Amplification and Expression of PAX7-FKHR and MYCN in a Human Rhabdomyosarcoma Cell Line Carrying a Cryptic t(1;13)(p36;q14). <i>Cancer Genetics and Cytogenetics</i> , 2000, 121, 139-145.	1.0	20
56	Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 754-761.	4.1	20
57	Immunological Prevention of a Multigene Cancer Syndrome. <i>Cancer Research</i> , 2004, 64, 8428-8434.	0.9	19
58	HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. <i>Oncotarget</i> , 2017, 8, 54444-54458.	1.8	19
59	Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells. <i>British Journal of Cancer</i> , 1993, 67, 674-679.	6.4	18
60	Expression of interleukin 15 (IL-15) in human rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma. , 1997, 71, 732-736.		17
61	Apc10.1: AnApcMin/+ intestinal cell line with retention of heterozygosity. <i>International Journal of Cancer</i> , 2004, 109, 200-206.	5.1	17
62	In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 1281-1286.	0.7	16
63	H-2Kb ANDH-2Db gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process. Involvement of integrin molecules. <i>International Journal of Cancer</i> , 1994, 59, 269-274.	5.1	16
64	New Target Antigens for Cancer Immunoprevention. <i>Current Cancer Drug Targets</i> , 2005, 5, 221-228.	1.6	16
65	Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. <i>Cancers</i> , 2019, 11, 1889.	3.7	15
66	Correlation between clinical response to antiandrogenic therapy and occurrence of receptors in human prostatic cancer. <i>Urology</i> , 1980, 16, 245-249.	1.0	14
67	Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination. <i>British Journal of Cancer</i> , 1992, 65, 519-522.	6.4	14
68	Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 599-610.	4.2	14
69	Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. <i>Oncogenesis</i> , 2021, 10, 77.	4.9	14
70	Colony-stimulating activity from the new metastatic TS/A cell line and its high- and low-metastatic clonal derivatives. <i>British Journal of Cancer</i> , 1985, 52, 215-222.	6.4	12
71	Systemic effects of cytokines released by gene-transduced tumor cells: Marked hyperplasia induced in small bowel by $\text{I}\beta$ -interferon transfectants through host lymphocytes. <i>International Journal of Cancer</i> , 1995, 61, 425-430.	5.1	12
72	Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. <i>Oncotarget</i> , 2014, 5, 108-119.	1.8	12

#	ARTICLE	IF	CITATIONS
73	Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells. <i>British Journal of Cancer</i> , 1998, 78, 1541-1546.	6.4	11
74	A Multi-DNA Preventive Vaccine for p53/Neu-Driven Cancer Syndrome. <i>Human Gene Therapy</i> , 2009, 20, 453-464.	2.7	11
75	Preclinical vaccines against mammary carcinoma. <i>Expert Review of Vaccines</i> , 2013, 12, 1449-1463.	4.4	11
76	Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. <i>Breast Cancer Research</i> , 2015, 17, 70.	5.0	11
77	Decreased adhesion to endothelial cells and matrix proteins of H-2Kb gene transfected tumour cells. <i>British Journal of Cancer</i> , 1993, 68, 862-867.	6.4	10
78	Inhibition of lung colonisation of a mouse mammary carcinoma by therapeutic vaccination with interferon-alpha gene-transduced tumor cells. <i>Clinical and Experimental Metastasis</i> , 1998, 16, 123-128.	3.3	10
79	Production of stem cell factor and expression of c-kit in human rhabdomyosarcoma cells: Lack of autocrine growth modulation. , 1998, 78, 441-445.		10
80	Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER2/neu oncogene-driven animal model system. <i>Proteomics</i> , 2010, 10, 3835-3853.	2.2	10
81	Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas. <i>Oncotarget</i> , 2014, 5, 11924-11938.	1.8	10
82	Therapy of murine mammary carcinoma metastasis with interferon γ and MHC gene-transduced tumour cells. <i>British Journal of Cancer</i> , 1996, 74, 1564-1569.	6.4	8
83	A Limited Autoimmunity to p185 ^{neu} Elicited by DNA and Allogeneic Cell Vaccine Hampers the Progression of Preneoplastic Lesions in HER-2/NEU Transgenic Mice. <i>International Journal of Immunopathology and Pharmacology</i> , 2005, 18, 351-363.	2.1	8
84	Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. <i>Pathology and Oncology Research</i> , 2007, 13, 336-339.	1.9	8
85	Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. <i>British Journal of Cancer</i> , 2012, 107, 1302-1309.	6.4	8
86	The prospects for cancer gene therapy. <i>International Journal of Immunopharmacology</i> , 2000, 22, 1025-1032.	1.1	7
87	APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. <i>European Journal of Cancer</i> , 2009, 45, 2731-2735.	2.8	7
88	Preclinical HER-2 Vaccines: From Rodent to Human HER-2. <i>Frontiers in Oncology</i> , 2013, 3, 151.	2.8	7
89	Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. <i>Cancers</i> , 2019, 11, 517.	3.7	7
90	Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis. <i>BMC Cancer</i> , 2019, 19, 126.	2.6	7

#	ARTICLE	IF	CITATIONS
91	INTERLEUKIN 6 GENE-TRANSFECTED MOUSE MAMMARY ADENOCARCINOMA: TUMOUR CELL GROWTH AND METASTATIC POTENTIAL. , 1997, 182, 76-85.		6
92	Immunoprevention of colorectal cancer: a future possibility?. Gastroenterology Clinics of North America, 2002, 31, 1001-1014.	2.2	6
93	Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft. Scientific Reports, 2021, 11, 1563.	3.3	6
94	Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. International Journal of Cancer, 2007, 121, 88-94.	5.1	5
95	HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines. Vaccine, 2011, 29, 4690-4697.	3.8	4
96	The Molecular Basis of Herpesviruses as Oncolytic Agents. Current Pharmaceutical Biotechnology, 2012, 13, 1795-1803.	1.6	4
97	Heterogeneity and Clonal Interactions in the TS/A Murine Mammary Adenocarcinoma. Advances in Experimental Medicine and Biology, 1988, 233, 5-14.	1.6	4
98	Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. Oncology Reports, 2007, 18, 451-6.	2.6	4
99	Is mts1 (S100A4) Gene Involved in the Metastatic Process Modulated by Gamma-Interferon?. Pathobiology, 1998, 66, 38-40.	3.8	3
100	Oncolytic herpes virus retargeted to HER-2. Cell Cycle, 2009, 8, 2859-2860.	2.6	3
101	Immunoprevention and Immunotherapy of Mammary Carcinoma. Breast Journal, 2010, 16, S39-S41.	1.0	3
102	OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis. OncoImmunology, 2018, 7, e1465164.	4.6	3
103	p185neu protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. International Journal of Cancer, 2000, 87, 186-194.	5.1	3
104	Interferon-Mediated Modulation of Metastasis and MHC Antigens. Advances in Experimental Medicine and Biology, 1988, 233, 129-139.	1.6	3
105	Dexamethasone modulation of in vitro growth pattern and of lung colonization ability in clones of a metastatic BALB/c mammary carcinoma cell line. Clinical and Experimental Metastasis, 1986, 4, 13-23.	3.3	2
106	Modulation by Ifn-Gamma of the Metastatic Ability of Murine, Human, and H-2-Transfected Tumor Cells. Tumori, 1989, 75, 383-388.	1.1	2
107	Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. European Journal of Cancer, 2006, 42, 680-687.	2.8	2
108	HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy. Cells, 2021, 10, 1808.	4.1	2

#	ARTICLE	IF	CITATIONS
109	Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells. <i>Oncology Reports</i> , 0, , .	2.6	2
110	Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. <i>Vaccine</i> , 2009, 27, 2065-2069.	3.8	1
111	HERPESVIRUSES AS ONCOLYTIC AGENTS. , 2012, , 223-250.		0